Eli Lilly and Co (XSWX:LLY) Tariff Resilience Score: 8/10 (As of Jun. 27, 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF955.00
GF Value CHF1,114.27
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Tariff Resilience Score?

Eli Lilly and Co XSWX:LLY +4.37% 100 Tariff Resilience Score is 8 as of Jun. 27, 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,114.27 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Eli Lilly and Co ranks better than 99.61% on this metric.

Eli Lilly and Co has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Eli Lilly and Co has Eli Lilly has a diversified global supply chain and significant pricing power in pharmaceuticals, reducing tariff impact. Its manufacturing is spread across multiple countries, and it benefits from industry-specific exemptions. Historical tariff changes have had minimal impact on its operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Eli Lilly and Co might have Highly Resilient.

Eli Lilly and Co  (XSWX:LLY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Eli Lilly and Co Tariff Resilience Score Related Terms

XSWX:LLY vs JNJ, ABBV, MRK: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Tariff Resilience Score falls into.


XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Eli Lilly and Co (XSWX:LLY) has a Tariff Resilience Score of 8 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Eli Lilly and Co ranks #4 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Eli Lilly and Co's Tariff Resilience Score too high?
Eli Lilly and Co's current Tariff Resilience Score is 8. Based on the distribution chart, Eli Lilly and Co ranks #4 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Tariff Resilience Score compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #4 out of 1031 companies for Tariff Resilience Score. This places Eli Lilly and Co in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Eli Lilly and Co's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,114.27, compared to a current price of CHF955.00 — trading 14.3% below its estimated fair value. The current Tariff Resilience Score is 8. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Tariff Resilience Score is 8 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF955.00 is trading 14.3% below its estimated GF Value™ of CHF1,114.27. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Tariff Resilience Score: 8
  • GF Value™: CHF1,114.27 vs. price of CHF955.00 (14.3% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF955.00
Price
CHF1,114.27
GF Value